share_log

Transcode Therapeutics | CORRESP: CORRESP

SEC ·  Jan 17, 2024 16:31

Summary by Futu AI

TransCode Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, as amended, to January 17, 2023. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence addressed to Mr. Tim Buchmiller at the SEC. The company, represented by interim CEO Thomas Fitzgerald, has indicated its awareness of the responsibilities entailed by the Act. TransCode Therapeutics has also provided contact details for its outside counsel, Goodwin Procter LLP, and has requested oral confirmation of the Registration Statement's effectiveness from the SEC upon approval.
TransCode Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, as amended, to January 17, 2023. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence addressed to Mr. Tim Buchmiller at the SEC. The company, represented by interim CEO Thomas Fitzgerald, has indicated its awareness of the responsibilities entailed by the Act. TransCode Therapeutics has also provided contact details for its outside counsel, Goodwin Procter LLP, and has requested oral confirmation of the Registration Statement's effectiveness from the SEC upon approval.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 345

Recommended